Sensing Contact Lens-based Device for 24-hour Monitoring of Intraocular Pressure

NCT ID: NCT03689088

Last Updated: 2018-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-22

Study Completion Date

2018-09-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glaucoma is characterized by irreversible vision loss through the progressive death of optic nerve fibers unless timely diagnosis and adequate treatment are provided. Medical therapy is aimed at lowering intraocular pressure (IOP) below a clinically determined target level in order to prevent or slow glaucoma progression. IOP is known to vary with the time of day as well as with daily activities.

The current way of assessing nycthemeral IOP fluctuation is to perform repeated discrete tonometry measurements, allowing only snapshot and non-continuous measurements once per hour in the best cases. The procedure is cumbersome, expensive, inconvenient (disturbed sleep cycle as patient is awoken for nocturnal/sleep period measurements) and may not detect crucial IOP values in time.

Sensimed AG has developed a new contact lens (CL)-based device intended to continuously measure IOP over 24 hours. The objective of this study is to investigate the use of device for 24-hour IOP monitoring in healthy subjects and glaucoma patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma, Open-Angle Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational device (Goldfish)

IOP will be monitored for 24 h in the Goldfish eye

Group Type EXPERIMENTAL

Goldfish

Intervention Type DEVICE

Goldfish will be placed in the eye for 24h monitoring

Tonometry

IOP will be acquired by standard tonometry at specific times in the the fellow eye

Group Type ACTIVE_COMPARATOR

Tonometry

Intervention Type DEVICE

Fellow eye will be measured by tonometry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Goldfish

Goldfish will be placed in the eye for 24h monitoring

Intervention Type DEVICE

Tonometry

Fellow eye will be measured by tonometry

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For Open Angle Glaucoma (OAG) subjects, a clinical diagnosis of primary OAG, including normal tension glaucoma (NTG) all known untreated IOP measurements \< 22 mmHg using Goldmann Applanation Tonometry (GAT) for NTG no IOP-lowering treatment; otherwise, a 4-week wash-out period prior to the recording
* For healthy subjects, no structural defects, normal visual fields, IOP ≤ 21 mmHg and open angles on gonioscopy
* Aged ≥ 18 years, either gender
* Body Mass Index ≤ 30 kg/m2
* Central Corneal Radius (flat meridian) between 7.5 mm (45 D) and 7.9 mm (42.75 D)
* Central Corneal Thickness between 500 microns and 600 microns
* Difference in IOP absolute value between eyes within 2.5 mmHg at screening in sitting position
* Same direction of IOP variation (positive or negative) for the 2 eyes when moving from sitting to supine positions at screening
* Spherical refraction within ±6.00 diopters and cylinder refraction within ±3.00 diopters
* Having given written informed consent, prior to any investigational procedures

Exclusion Criteria

* Ocular pathology (other than glaucoma for glaucoma subjects)
* Previous glaucoma, cataract or refractive surgery
* Corneal or conjunctival abnormality, precluding contact lens adaptation
* Severe dry eye syndrome
* Subjects with allergy to corneal anesthetic
* Subjects with contraindications for silicone CL wear
* Subjects with contraindications for Water Drinking Test (WDT) (eg., heart, renal problems)
* Subjects unable or unwilling to comply with the study procedures
* Participation in other interventional clinical research within the last 4 weeks
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sensimed AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Wasilewicz, MD

Role: PRINCIPAL_INVESTIGATOR

[W]-Eye Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

[W]-Eye clinic

Poznan, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GF-1703

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Smart Soft Contact Lenses for Monitoring Glaucoma
NCT07224542 ENROLLING_BY_INVITATION NA
SENSIMED Triggerfish in Closed Eyes
NCT01938287 COMPLETED PHASE4